title: Cardioprotective effects and underlying mechanisms of oxymatrine against Ischemic myocardial injuries of rats.
abstract: Oxymatrine has been demonstrated to have a variety of pharmacological actions. Accumulating evidence indicates that oxymatrine may exert a protective effect on the cardiovascular system. The study was designed to explore the possible role of oxymatrine against myocardial ischemic damage and several related signaling pathways as potential mechanisms. The protective properties of oxymatrine were studied in a rat model of acute myocardial infarction due to permanent ligation of the left anterior descending coronary artery. The results showed that administration of oxymatrine relieved myocardial injuries during ischemia, and this was achieved by protecting cardiomyocytes from apoptotic death. The beneficial effects of oxymatrine were likely mediated by an inhibition of lipid peroxidation (MDA production) and an increase in endogenous antioxidant activity (SOD), activation of the survival signaling molecule (Bcl-2), and a reduction of apoptotic mediator (Fas) and intracellular Ca2+ overload.
authors.affiliation: Department of Pharmacology, Harbin Medical University, Bio-Pharmaceutical-Engineering Key Laboratory of Heilongjiang Province-Incubator of State Key Laboratory, Harbin 150081, P. R. China.
authors.forename: Sun
authors.initials: S
authors.lastname: Hong-Li
authors.forename: Li
authors.initials: L
authors.lastname: Lei
authors.forename: Shang
authors.initials: S
authors.lastname: Lei
authors.forename: Zhao
authors.initials: Z
authors.lastname: Dan
authors.forename: Dong
authors.initials: D
authors.lastname: De-Li
authors.forename: Qiao
authors.initials: Q
authors.lastname: Guo-Fen
authors.forename: Liu
authors.initials: L
authors.lastname: Yan
authors.forename: Chu
authors.initials: C
authors.lastname: Wen-Feng
authors.forename: Yang
authors.initials: Y
authors.lastname: Bao-Feng
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D019085:Fluorescent Antibody Technique, Direct; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009203:Myocardial Infarction / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008517:Phytotherapy; D011807:Quinolizines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000097:blood; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; D008315:Malondialdehyde; D011807:Quinolizines; D013482:Superoxide Dismutase; C037573:oxymatrine; D000093842:Matrines